Market Access News | pharmaphorum

Monday 9 November 2026

News

News

Tariffs spelled out with Scrabble letters

Tariffs 'could cancel out discounts with biosimilars'

Tariffs on US pharma imports could remove discounts offered to health systems by biosimilars and threaten the future of the sector, says a non-profit.

News

There's good news for RSV jab firms at delayed ACIP meeting

There's good news for RSV jab firms at delayed ACIP meeting

GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.

News

FDA clears first migraine DTx from Click Therapeutics

FDA clears first migraine DTx from Click Therapeutics

Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US.

News

President Trump on a podium

Trump pledges drug price cuts – and action on 'pill penalty'

A Trump executive order aimed at lowering drug prices includes a plan to do away with what industry claims is a flaw in the Inflation Reduction Act.

News

J&J chief executive Joaquin Duato

J&J expecting $400m hit from tariffs in 2025

J&J chief executive Joaquin Duato has told analysts that tax policy, not tariffs, is the key to increasing pharma manufacturing capacity in the US.

News

Approved stamp across boxes of Leqembi

After delay, Alzheimer's drug Leqembi gets green light in EU

The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.